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Abstract
Migraine affects14% of the world’s population, though not all predisposing causal risk factors are known. We used electronic
health records, genetic co-heritability analysis, and a two-sample Mendelian Randomization (MR) design to determine if elevated
serum calcium levels were associated with risk of migraine headache. Co-morbidity was evaluated using electronic health records
obtained from the PennOmics database comprising>1 million patient entries. Genetic co-heritability and causality via MR was as-
sessed using data from the International Headache Consortium (23,285 cases, 95,425 controls) and circulating serum calcium levels
(39,400 subjects). We observed co-occurrence of migraine and hypercalcaemia ICD-9 diagnoses (OR¼1.58, P¼4 1013), even after
inclusion of additional risk factors for migraine (OR¼1.23, P¼2 103). Second, we observed co-heritability (rg¼0.191, P¼0.03) be-
tween serum calcium and migraine headache, indicating that these traits have a genetic basis in common. Finally, we found that
elevation of serum calcium levels by 1 mg/dl resulting from our genetic score was associated with an increase in risk of migraine
(OR¼1.80, 95% CI: 1.31–2.46, P¼2.5 104), evidence supporting a causal hypothesis. We also present multiple MR sensitivity
analyses in support of this central finding. Our results provide evidence that hypercalcaemia is comorbid with migraine headache
diagnoses, and that genetically elevated serum calcium over lifetime appears to increase risk for migraine. Further studies will be
required to understand the biological mechanism, pathways, and clinical implication for risk management.
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Introduction
Migraine is the most common neurological disorder in the
world with over a billion afflicted (1), with elevated prevalence
in women versus men of European ancestry (2). A highly debili-
tating disorder, it ranks among the costliest in terms of eco-
nomic impact and lost productivity (3). Migraine is classified
into two common forms: migraine with and without aura, an
associated perceptual distortion that occurs before or close to
the onset of migraine (4). Genome-wide association studies
have demonstrated numerous genetic factors that underlie sus-
ceptibility to migraine generally (5), suggestive of a common
aetiology between migraine with and without aura. An impor-
tant next step is to translate these data into clinically relevant
insights of causal mechanisms underlying the disorder.
Identification of causal factors for migraine is critical to suc-
cess in translational medicine. Specifically, interventions based
on causal factors have the best chance for success in ameliorat-
ing disease. While the Randomized Control Trial is the standard
to assess causal relationships, such trials are expensive, time-
consuming, and ultimately require knowledge of an intervention
hypothesized to be clinically beneficial. Thus, research efforts
generating compelling evidence for causal hypotheses offer the
best chances for translational clinical outcomes to emerge.
Epidemiological studies can provide evidence of association
between measurable biomarkers and risk to disease. However,
these studies often require knowing what biomarker will be
studied at the start of the study, and often cannot survey all
possible traits. For example, a tumour within parathyroid
glands can cause primary parahyperthyroidism (6), resulting in
excess secretion of parathyroid hormone and circulating levels
of serum calcium, with severe headache as a common symp-
tom. Given the sporadic nature of this disease, it is challenging
to evaluate the relationship between elevated parathyroid hor-
mone or serum calcium levels with a disposition to headache,
with only anecdotal reports scattered in the literature (7–9).
While not perfect, biomedical informatics mining of electronic
health records could provide one complementary source of data
to identify potential and plausible candidate traits like these for
further study (10).
Once correlated risk factors have been identified, a suite of
computational methods can provide direct evidence for and
against causal hypotheses using human genomics data (11–13).
One approach, termed Mendelian Randomization, uses genetic
variants associated with a biomarker of interest in an instru-
mental variable analysis to estimate a causal effect of the bio-
marker on a disease endpoint. The approach has some analogy
to the classic Randomized Control Trial, where genotype oper-
ates as the randomized intervention (14,15). Because alleles are
sorted randomly at birth and the assumption that trait end-
points do not change germline variation, the approach avoids
issues due to reverse causality. In addition, careful selection of
genetic variation for testing can address issues of confounding.
While these methods require several key assumptions to hold,
application of the approach has been used extensively to gener-
ate evidence for (16) and against (17) specific causal hypotheses,
importantly where clinical trial data is not readily available. A
second, recently described approach estimates genetic correla-
tion – joint heritability – between a pair of traits (18).
Application of the approach recapitulates expected causal asso-
ciations such as low-density lipoprotein cholesterol and heart
disease, as well as obesity and T2D, though one limitation of the
approach is that this does not provide a direction of effect be-
tween the trait and endpoint. Nonetheless, both approaches are
complementary towards evaluating causal hypotheses using
genomics data.
Serum calcium level is a continuous, quantitative biomarker
that is maintained within a homeostatic range. The prevalence
of extreme levels of circulating serum calcium (diagnosed as
hypercalcaemia) has a range of underlying causes in the general
population and is difficult to estimate given its frequency,
though has been observed in 0.5–1% of patients who visit emer-
gency departments (39). Genetic variation associated with
population-level variability in serum calcium levels have also
been reported (19), allowing the opportunity to apply the above
approaches—mining electronic health records, estimation of
genetic heritability, and direct causal inference testing—to eval-
uate the hypothesis that serum calcium is a causal risk factor
for migraine headache. Here, we use biomedical electronic
health records to show a correlation between elevated calcium
levels and migraine, and subsequently large-scale genetic data
sets to test the hypothesis that genetically elevated serum cal-
cium levels increase risk for migraine headache.
Results
Hypercalcaemia and migraine headache are diagnoses
that occur together frequently
Large-scale epidemiological association studies have not sys-
tematically examined a potential correlation between serum
calcium levels and migraine headache. Thus, we aimed to test
the hypothesis that Migraine headache diagnoses are associ-
ated with elevated serum calcium levels, diagnosed as hypercal-
caemia. To do this, we obtained ICD-9 diagnosis codes in over 1
million de-identified health records curated as part of the
PennOmics resource (Methods), quantifying the odds that a
Migraine Headache diagnoses (MHD) co-occurs in the patient re-
cord with another ICD-9 diagnosis code (Methods). We observed
co-occurrence between MHD ICD-9 codes and ICD-9 codes for
Hypercalcaemia (OR¼ 1.58, P¼ 4.75  1013, Supplementary
Material, Table S2), including adjustments for age, sex, and
ancestry. These data are consistent with the hypothesis that
migraine and elevated serum calcium levels (diagnosed as
hypercalcaemia) occur together frequently in the electronic reg-
istry of our patient cohort.
A migraine headache may have additional contributing fac-
tors or co-diagnoses that might occur, potentially confounding
our initial analysis. Consequently, we looked for additional di-
agnoses that frequently occurred along with migraine headache
in our patient records. We found that MHD was co-diagnosed
with hypothyroid, hypertension, and hyperlipidemia (OR¼ 1.44,
1.48, and 1.80, each P< 1050, Table 1), as well as hyperparathy-
roid (OR¼ 0.75, P¼ 1.25  103, Table 1). After including all of
these additional factors into the previous model, we again ob-
served co-occurrence for MHD with a diagnosis of hypercalcae-
mia (OR¼ 1.23, P¼ 1.75  103, Table 1). These data are
consistent with the hypothesis that migraine headache and ele-
vated serum calcium levels are frequently diagnosed together,
independently of other important diagnoses that also occur
with migraine.
Evidence of a common genetic basis between serum
calcium levels and migraine headache
If serum calcium has a genetic link to migraine headache, ge-
netic risk factors should be shared in common across the entire
genome, and therefore, both traits would share genetic
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heritability. To test this hypothesis, we obtained genome-wide
association data for both serum calcium levels and migraine
headache (5,19), and estimated genetic correlation between
both traits (all subjects, Methods). In this analysis, we observed
a moderate genetic correlation between migraine and calcium
levels (rg¼ 0.19, 95% CI: 0.02–0.36, P¼ 0.03), rejecting the hypoth-
esis that these traits are independent of one another, and evi-
dence that serum calcium levels and migraine headache may
have a genetic basis in common.
Genetically elevated serum calcium levels are
associated with migraine headache
We next turned to directly test the hypothesis that elevated
serum calcium levels cause increased susceptibility to mi-
graine headache, using a two-sample Mendelian Randomization
study design. We constructed a risk score using all eight ge-
netic factors associated with serum calcium levels (Fig. 1,
Supplementary Material, Table S3, Methods). This genetic instru-
ment explained 1.25% of the variability in serum calcium levels,
and was sufficient strength to minimize effects from weak
instrument bias for our analysis of migraine headache
(F-statistic¼ 118.9). Based on 23,285 migraineurs and 95,425 con-
trols (5), we found that elevation of serum calcium levels by a
hypothetical 1 mg/dl resulting from our genetic score was associ-
ated with an increase in risk of migraine (OR¼ 1.80, 95% CI: 1.31–
2.46, P¼ 2.5  104, Table 2). Furthermore, when stratified by
aura status, we found that elevation of serum calcium levels by
a hypothetical 1 mg/dl resulting from our genetic score was asso-
ciated with an increase in risk of migraine with (OR¼ 2.66, 95%
CI: 1.41–5.02, P¼ 2.6  103, Table 2) or without aura (OR¼ 2.57,
95% CI: 1.49–4.43, P¼ 6.6  104, Table 2).
Next, we identified four genetic risk factors exclusively as-
sociated with serum calcium levels and their effects
(Supplementary Material, Table S3, Methods). This genetic in-
strument explains 0.87% of the variability in serum calcium lev-
els and has sufficient strength to minimize effects from weak
instrument bias for our analysis of migraine headache
(F-statistic¼ 82.5). We estimated the causal effect of genetic ele-
vation of serum calcium levels with migraine headache, using a
genotype risk score method (Methods). We found that elevation
of serum calcium levels by a hypothetical 1 mg/dl resulting from
this exclusive genetic score was associated with an increase in
risk of migraine (OR¼ 1.81, 95% CI: 1.24–2.63, P¼ 2  103,
Table 2). Furthermore, when stratified by aura status, we found
that elevation of serum calcium levels by a hypothetical 1 mg/dl
resulting from our genetic score was associated with an in-
crease in risk of migraine with (OR¼ 2.72, 95% CI: 1.27–5.81,
P¼ 9.8  103), or without aura (OR¼ 2.84, 95% CI: 1.50–5.40,
P¼ 1.4  103, Table 2). As the confidence intervals for these
aura-stratified analyses included the causal effect estimate
based on the entirety of the data, we conclude that the esti-
mates stratified by aura status are not statistically different
from the unstratified analysis.
Sensitivity analysis for the serum calcium genetic
instruments using alternative causal inference methods
We next evaluated the robustness of our primary observation
by applying a suite of sensitivity analyses. First, an unweighted
risk score based on all serum-calcium variants was associated
with an increased risk of migraine in all samples (P¼ 2.9  103,
Table 2) or stratified by aura (P¼ 0.011 with aura, P¼ 0.037 with-
out aura, Table 2), suggesting that our result is robust to the
choice of weights used in our risk score. We next obtained a
weighted-median estimate for the causal effect using all vari-
ants, an approach that generates a causal estimate analogous to
the risk score method used above. This approach is unbiased as-
ymptotically but only requires 50% or more of the weight for the
score to derive from valid instruments, a less stringent require-
ment compared to the GRS score method (40). The weighted-
median estimated for 1 mg/dl genetic elevation of serum
calcium on migraine risk agreed with estimates from the analy-
sis above which included all samples (OR¼ 1.92, 95% CI: 1.30–
2.84, P¼ 1.6  103, Table 2), or analysis that stratified either
with aura (OR¼ 2.73, 95% CI: 1.29–5.97, P¼ 9.6  103, Table 2) or
Table 1. Phenotypic co-occurrence between migraine headache, demographics, hypercalcaemia, and other risk factors. Adjusted odds ratio
(OR) and estimates from logistic regression, including Age, Sex, hypertension, hyperlipidemia, hypothyroidism, hyperparathyroidism, and
hypercalcaemia
Overall with MHD Without MHD Adjusted OR of
Variables n¼1038457 n¼29607 n¼1008850 MHD (95% CI) P-value
Age (overall)a 0.85 (0.84–0.86) <0.001
Mean (SD) 48.7 (21.7) 45.9 (15.5) 48.7 (21.9)
%b %c %c
Sex
Male 439862 (42.4%) 5272 (1.2%) 434590 (98.8%) 1.00
Female 598595 (57.6%) 24335 (4.1%) 574260 (95.9%) 3.69 (3.58, 3.80) <0.001
Race
Black 314045 (30.2%) 7850 (2.5%) 306195 (97.5%) 1.00
White 724412 (69.8%) 21757 (3.0%) 702655 (97%) 1.38 (1.34, 1.42) <0.001
Diagnosis, Yes
Hyperlipidemia 203393 (19.6%) 7812 (3.8%) 195581 (96.2%) 1.80 (1.74, 1.87) <0.001
Hypertension 234285 (22.6%) 8042 (3.4%) 226243 (96.5%) 1.48 (1.43, 1.54) <0.001
Hypothyroid 57846 (5.6%) 2976 (5.1%) 54870 (94.8%) 1.44 (1.38, 1.50) <0.001
Hyperparathyroid 5190 (0.5%) 148 (2.9%) 5042 (97.1%) 0.75 (0.64–0.90) 1.25  103
Hypercalcaemia 6306 (0.6%) 270 (4.3%) 6036 (95.7%) 1.23 (1.08–1.40) 1.75  103
aReference is for computation of OR per 10-year increase in age.
bProportions are within the columns.
cproportions are across rows.
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without aura (OR¼ 3.60, 95% CI: 1.81–6.85, P< 2  104, Table 2).
To evaluate the potential for systematic bias in our data, we ap-
plied Egger regression to estimate bias and a causal effect in the
context of bias (25). However, we did not observe evidence of
bias (P> 0.15 for all instruments, Table 2), and found a modest
association for the score that included all migraine-affected
subjects (P¼ 0.037, Table 2). To further evaluate the potential of
bias and violation of the no measurement error (NOME)
assumption, we applied the recently reported SIMEX approach
(41). We found that each of our scores had a high I2 (Table 2) in-
dicative of a robust genetic instrument, and our estimated
causal effects were similar to that obtained by Egger Regression,
with modest association for scores using all migraine-affected
or those with aura (P< 0.05, Table 2). Finally, we excluded our
strongest variant from our constructed instrument (rs1801725,
CASR). We observed modest nominal association using all
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Figure 1. Summary SNP association data for each serum calcium variant for migraine. The effect size of the effect on serum calcium is given in units of mg/dl. (A) All
samples. (B) Subset of migraine patients with aura. (C) Subset of migraine patients without aura. OR, Odds Ratio; CI, Confidence Interval.
Table 2. Summary statistics for genetic instruments used for causal inference analysis for serum calcium for migraine traits
All Samples With Aura Without Aura
Odds Ratioa (95% CI) P Odds Ratio (95% CI) P Odds Ratio (95% CI) P
Analyses using All Variants (n58)
Cumulative GRSb 1.80 (1.31–2.46) 2.5 104 2.66 (1.41–5.02) 2.6 103 2.57 (1.49–4.43) 6.6 104
Unweighted GRSb 1.66 (1.19–2.31) 2.9 103 2.43 (1.22–4.82) 0.011 1.87 (1.04–3.38) 0.037
Weighted-median GRSc 1.92 (1.30–2.84) 1.6 103 2.73 (1.29–5.79) 9.6 103 3.60 (1.81–6.85) <2.0 104
Egger Regression (Causal Effect)c 1.97 (1.05 -3.69) 0.037 2.70 (0.78–8.75) 0.11 5.42 (1.73–16.19) 2.2 103
Egger Regression (Bias Term)d 0.003 (0.025–0.019) 0.74 0.0007 (0.048–0.046) 0.97 0.026 (0.065–0.013) 0.16
SIMEX MR-Egger (Causal Effect)d 2.01 (1.05–3.80) 0.037 2.85 (1.32–6.17) 0.021 5.80 (0.91–37.0) 0.066
SIMEX I2 (weighted) 0.933 0.943 0.938
Analyses using Serum Calcium Exclusive variants (n54)
Cumulative GRSb 1.81 (1.24–2.63) 2.0 103 2.72 (1.27–5.81) 9.8 103 2.84 (1.50–5.40) 1.4 103
Unweighted GRSb 1.61 (1.06–2.45) 0.025 2.45 (1.06–5.64) 0.036 1.86 (0.88–3.93) 0.10
aOdds ratios are given in units of fold increase in migraine risk per unit increase in serum calcium (1 mg/dl).
bP-value and 95% CI from the normal distribution.
cP-value and 95% CI calculated by bootstrapping (n¼10,000).
dP-value and 95% CI calculated from the Student’s t distribution.
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migraineurs (Supplementary Material, Table S4), consistent
with an attenuated, residual contribution to migraine across all
serum calcium loci. Taken collectively, these analyses suggest
that inference is robust to the weights we selected for our ge-
netic instruments, and our inference that genetically elevated
serum calcium levels increase susceptibility to migraine head-
ache does not seem to have evidence of clear violations in
several specific assumptions made in our Mendelian
Randomization analysis.
Discussion
Causal inference is one of the most challenging and important
problems in biology and medicine. To achieve impactful trans-
lational outcomes efficiently, identification of causal risk factors
is crucial. Computational approaches that rapidly facilitate
causal hypothesis testing using the approaches we describe
here are designed to begin the process of building a compelling,
evidence-based case for causality, complementing or perhaps
even motivating future experimental activities in models sys-
tems and in humans. We present three lines of support for an
association between serum calcium levels and susceptibility to
migraine headache: (i) comorbidity analysis using electronic
health records indicates that diagnoses for migraine and serum
calcium (using hypercalcaemia as a proxy) occur in patient re-
cords together more than expected, (ii) genetic heritability anal-
ysis indicates that serum calcium and susceptibility to migraine
headache may have a genetic basis in common, and (iii) a ge-
netic risk score analysis in the Mendelian Randomization
framework indicates that a hypothetical 1 mg/dl genetic in-
crease in serum calcium levels is associated with a 1.8-fold in-
crease in risk to migraine headache. Taken collectively, these
data support an epidemiological and genetic correlation, and a
potentially causal connection between levels of circulating cal-
cium and susceptibility to migraine.
As an alternative to epidemiological data, which in our case
was not available, we extracted diagnosis ICD-9 codes from>1M
electronic health records as a proxy. This design does have
some limitations that should be acknowledged. First, the diag-
nosis codes of migraine that we obtained may not reflect a true
clinical diagnosis of migraine headache obtained from a trained
neurologist. Because the data are de-identified, we are not able
to go back and ‘verify’ the diagnoses that are listed, or check
specific biomarker measurements in patients (i.e. levels of se-
rum calcium) in a comprehensive way. It may be important in
the future to consider systematic, computational diagnosis of
migraine headache using known affected subjects within the
health record data to train a model to make accurate predictions
of which subjects have clinically defined migraine headache.
Second, because the collection of diagnoses begins at 2008, we
are not able to determine the order of diagnoses. Thus, our anal-
ysis here may be susceptible to reverse causality, as is the case
with other types of correlational studies, as well as confounding
from factors that we did not include in our analysis.
Despite these limitations, there is some indication that our
association does match previous epidemiological reports.
Features of metabolic syndrome (hypertension, hyperlipid-
emia), as well as sex and hypothyroid are all positively associ-
ated with migraine (27–30), and our findings match these
previous observations. As hyperparathyroidism is a frequent
cause of hypercalcaemia, it is somewhat curious why the ad-
justed co-occurrence is in the opposite direction. At face, this
implies that in the context of a patient presenting metabolic
syndrome traits and features of headache, hyperparathyroid is
less often diagnosed. Further work would be required to rule out
ascertainment against the diagnosis.
We also performed a genetic correlation analysis, to provide
additional evidence supporting a relationship between these
two traits. We note that this type of correlation evidence is
different from, but complementary to, the Health record co-
morbidity analysis. Genetic correlation not only connects di-
rectly to the quantitative trait measured (serum calcium levels),
but also directly estimates correlation between traits due to ge-
netics, which should be correlated if a causal hypothesis is true.
However, this analysis does not immediately give a direction for
the relationship between traits, and still could be subject to con-
founding due to directional bias from unknown, pleiotropic
associations.
Using the framework of Mendelian Randomization, large-
scale genetic studies provide one of many pieces of evidence in
support of consistent and robust causal relationships between
measurable biomarkers and risk of clinical endpoints. However,
the Mendelian Randomization analyses we performed here also
have limitations that should be acknowledged. First, our analy-
sis requires (i) a potent genetic instrument and effect on serum
calcium, (ii) that the serum calcium genetic variants are not as-
sociated with one or more unmeasured confounding variables
which also increase risk of migraine, and (iii) that the effect of
change in migraine through our selected genetic instruments
are mediated entirely through serum calcium levels. We as-
sessed several of these assumptions in turn. While our genetic
instrument explained 1% of the variability in serum calcium
levels, this was a sufficiently strong to minimize weak residual
bias, assessed by F-statistic. While we cannot completely rule
out additional confounding, we did examine the association of
our SNP panel against a number of cardiometabolic traits, iden-
tifying a subset that was free of metabolic associations. We also
generated causal effect estimates using both unweighted and
weighted-median risk scores, and our results were consistent
with the full genotype risk score approaches and suggest our in-
ference is robust to potentially invalid instrument contributing
to our score. Furthermore, we utilized Egger’s regression and
the SIMEX approach to evaluate systemic bias from our genetic
instruments, and did not reject the null hypothesis of no bias.
However, our negative results here do not completely rule out
all forms of potential biases. While the MR analysis of the sub-
strata estimated a higher causal effect than the entire popula-
tion (Table 2), this could be reasonably explained by the fact
that the ‘all sample’ migraine meta-analysis data includes stud-
ies that were not present in either of the aura stratified
analyses.
Calcium channel blockers (CCBs) are often used as a mi-
graine prophylactic, thus possibly implicating Ca2þ into the aeti-
ology of migraine. However, the mechanism of action of these
drugs is thought to target the vascular aetiology of migraine, e.g.
lower cerebral vasoconstriction by reducing Ca2þcellular influx
(31,32). A recent meta-analysis of clinical trials data from a
range of CCBs found no difference in reduction of migraine
headaches relative to placebo (33), though clearly more data on
specific drugs are required. Furthermore, CCBs may not ulti-
mately impact levels of serum calcium, except in extreme cases,
as changes in serum calcium levels are probably compensated
by changes in levels of parathyroid hormone to maintain ho-
meostasis. One possibility is that certain CCBs may act to raise
parathyroid hormone by lowering serum calcium though hyper-
calciuria (34), which would be a possible, additional mechanism
of action for some of these drugs that is consistent with our
findings. Overall, our results suggest that direct targeting of
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Ca2þ levels – in addition to the known vasodilatory effect of
CCBs – may offer additional therapeutic benefits.
One of the variants we studied was rs1801725, a coding mis-
sense mutation (Ala986Ser) in the calcium sensing receptor
gene, CASR. Indeed, the observed association at this genetic var-
iant contributes heavily in our Mendelian Randomization result,
in addition to the aggregated contribution of weaker serum cal-
cium association in our risk score analysis. CASR is expressed in
the parathyroid gland and kidney where it detects changes in
circulating calcium levels and relays this information back to
intracellular signalling pathways to regulate calcium homeosta-
sis via secretion or absorption (35). Rare mutations in CASR can
cause Mendelian forms of either hypercalcaemia (if loss of func-
tion) or hypocalcaemia (activating mutations). Here, the alanine
residue at this site is a conserved amino acid (back to the model
fish, Stickleback); carriage of the serine allele is associated with
elevated serum calcium levels, consistent with a hypomorphic
function CASR with carriage of serine at this position. Given the
evidence from Mendelian disease studies, evolutionary con-
straint at this site, and that this presumed hypomorphic allele
is coding, a strong hypothesis is that this variant is indeed
causal, though functional assays are necessary to demonstrate
the effect of this variant formally.
Because the serine allele is also associated with increased
susceptibility to migraine headache (P¼ 3.8  103), one hypoth-
esis is that modest pharmacological CASR agonism would both
lower serum calcium and protect against migraine headache.
Cinacalcet, an FDA approved agonist of CASR marketed as
Sensipar, is approved in treatment for the limited indications of
secondary hyperparathyroidism or hypercalcaemia in patients
with parathyroid carcinoma. While the drug has a narrow appli-
cability owing to the potential risk of hypocalcaemia, along with
additional adverse side effects (nausea, muscle or chest pain,
and osteoporosis), it still may be worthwhile to explore the
repurposing potential of this compound for treatment of mi-
graine headache in specific instances.
Our comorbidity analysis, while providing some correlation
between hypercalcaemia and migraine, suggest the potential
clinical impact. While patients with hypercalcaemia are poten-
tially rare diagnoses overall (0.6% in our cohort), 1% of migraine
subjects were also diagnosed with hypercalcaemia. If we as-
sumed that elevated calcium levels were causal for migraine
susceptibility, the implication is that this small population of
migraineurs (1%) could be managed by returning their serum
levels to homeostatic levels. There could also remain a larger
population of subjects who have undiagnosed hypercalcaemia,
or even levels of serum calcium that are higher than the popula-
tion average but who are otherwise sub-clinical, who could be
tested (and potentially treated) in a similar manner. An impor-
tant consideration here is if the amount of change in serum cal-
cium we note is actually obtainable to achieve a clinical benefit.
We demonstrate that genetic elevation of serum calcium by
1 mg/dl increase was associated with increased odds or mi-
graine headache by 1.8-fold. One study has shown that>85% of
patients taking Sensipar had their serum calcium levels de-
creased by>1 mg/dl (36); a second study demonstrated a me-
dian difference of 1 mg/dl for treated versus placebo controls
(37). These clinical trials indicate that the level of change in se-
rum calcium associated with migraine risk is, in fact, clinically
obtainable.
In summary, we provide evidence supporting the correlation
in diagnoses of serum calcium levels (quantified as hypercal-
caemia) and migraine headache, independent of additional, po-
tentially confounding risk factors. In addition, we provide
evidence for shared narrow-sense genetic heritability, using
large-scale data from human populations studied separately for
serum calcium levels and migraine headache. Finally, we found
that genetic variants exclusively associated with circulating cal-
cium levels are associated with migraine headache, providing
evidence of a causal relationship between elevated serum cal-
cium levels over a lifetime and migraine headache.
Materials and Methods
Description of the PennOmics resource
PennOmics is a data warehouse that integrates research and
clinical data from several separate data storage resources from
area hospitals affiliated with the University of Pennsylvania
Health System (UPHS). This includes records stored at the Penn
Data Store (PDS), the Cancer Center tumour registry, the Velos
Clinical Trial Management System, and genomics data from
contributing clinical and research labs throughout UPHS.
Records and clinical data contained in PennOmics are continu-
ally updated (>3 million potential patient records are contained
there as of this writing) and are completely de-identified, mean-
ing all direct patient identifiers have been removed, including
adjustment of patient age information to further obfuscate the
identification of individual subjects. Details for the prevalence
of each ICD-9 diagnosis codes and demographic data used in
this study are provided in Table 1.
Comorbidity analysis for ICD-9 codes using the
PennOmics resource
ICD-9 diagnoses and demographic patient information from the
PennOmics resource, comprising 1,098,023 subjects with records
collected after 2008, was queried on November 6th, 2015.
Initially, we obtained all diagnoses for subjects where sex and
age (in years) was present, in non-hispanic and White
(n¼ 724,412) and Black (n¼ 314,045) reported ethnicities.
Hispanic white samples were excluded here, owing to the small
number of reported MHD diagnoses given the total number of
samples present in this extracted collection. For each individ-
ual, binary variables for each phenotype group were con-
structed, which included (i) migraine headache, (ii)
hypercalcaemia, (iii) hypertension, (iv) hyperlipidaemia, (v) hy-
pothyroid, and (vi) hyperparathyroid, based on available ICD-9
codes in the resources (Supplementary Material, Table S1). A
subject was labelled ‘1’ for the given variable if any of these as-
signed ICD-9 codes were present in the record, otherwise ‘0’. We
used logistic regression (implemented in R (3.13), using glm(), bi-
nomial link function) to report the odds of co-occurrence of the
migraine headache ICD-9 status diagnosis code with ICD-9 code
variables for hypercalcaemia, including hypertension, hypothy-
roid, hyperparathyroid or hyperlipidaemia, age, and sex as addi-
tional covariates. These factors were selected given previous
reports of correlation with migraine (27–30). Results are pre-
sented for the analysis that included ancestry as an additional
covariate in the model, which were qualitatively similar when
each ethnicity was analyzed individually (Supplementary
Material, Table S2).
Heritability analysis for migraine headache and serum
calcium levels
We used the bivariate heritability estimation method imple-
mented in LDSC (v1.0.0) to estimate the genetic correlation
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between migraine and serum calcium levels. The details of the
method are described elsewhere (18). Briefly, assuming a poly-
genic model, the genetic correlation between two traits can be
estimated using the summary association statistics (i.e. p-val-
ues converted to Z-scores via inverse-normal transformation)
for both traits and for all tested genetic variants included in a
genome-wide association panel, and the ‘LD score’, which mea-
sures the amount of genetic variation tagged (i.e. in linkage dis-
equilibrium) by the SNP (38). Under some assumptions, the
slope of the regression of the product of the association Z-
scores on the LD score can be used to estimate the genetic corre-
lation between the two traits. Precise details of the method, its
efficiency, and accuracy are described elsewhere (38). For this
analysis, we utilized common variants that were present in the
Hapmap3 reference (20), which were also genotyped across
most of the sample: specifically, the number of analyzed sam-
ples not less than two-thirds of the 90th percentile of the total in
each meta-analysis. We obtained summary GWAS data for se-
rum calcium levels from a recent report (19), which involve an
inverse-variance fixed-effects Hapmap reference panel-based
imputation meta-analysis of 17 population-based cohorts of
European descent, all measured for circulating serum calcium
levels. For migraine headache, we utilized association data from
a recent report, based on an inverse-variance fixed-effects
Hapmap reference panel-based imputation meta-analysis in-
cluding 29 cohorts of European ancestry (5). In brief, contribut-
ing cohorts derived mostly from northern European (Finland,
Germany, Netherlands, UK, Iceland, Sweden, Norway, Estonia,
etc.), with cases/controls were matched within each study.
Stratification was further controlled by inclusion of principal
components for genetic similarity as covariates in the associa-
tion analysis by each study. From these data, all subjects diag-
nosed with migraine headache included 23,285 individuals with
migraine (cases defined from both population and clinically de-
fined cohorts) and 95,425 population-matched controls.
Construction of genetic instruments for Mendelian
randomization analysis
We used our previous reported tool, MeRP, to perform instru-
ment construction and testing (21). Briefly, the National Human
Genome Research Institute (NHGRI) maintains a compilation of
data from GWAS publications (22), and was used as our starting
point. All (n¼ 8 total) serum calcium single nucleotide poly-
morphic (SNP) associations that were genome-wide significant
(P< 5  108) were obtained. These SNPs then went through fil-
tering steps for LD and confounding trait associations. First, as-
sociations with potential confounding traits were assayed from
within the NHGRI GWAS catalog and a summary file containing
association p-values for>2 million SNPs and 15 cardio/meta-
bolic traits (these included blood pressure, cholesterol, anthro-
pometric and obesity, glucose/insulin, along with type 2
diabetes and coronary heart disease) obtained from the public
domain, and violating SNPs were removed. The remaining SNPs
were grouped together based on pairwise LD (r2>0.05) and the
SNPs with the lowest trait associated p-value value from each
LD group were selected to comprise the serum calcium genetic
variants for MR analysis. This resulted in four (n¼ 4: rs7336933,
rs1801725, rs10491003, rs1570669) SNPs exclusively associated
with serum calcium levels that comprised our final, serum cal-
cium instrument for MR testing. The list of exclusive and non-
exclusive serum calcium (n¼ 4: rs780094, rs17711722, rs7481584,
and rs1550532) associated SNPs along with annotations for
nearest genes are provided (Supplementary Material, Table S3).
Phenotypic associations for non-exclusive variants includes the
following: rs780094 has multiple established trait associations
(P< 5  108) with triglycerides, total cholesterol, Height, fasting
glucose; rs17711722 was nominally associated (P< 0.05) with tri-
glycerides, body mass index (BMI), 2-hour glucose, fasting insu-
lin, and HOMA-IR; rs7481584 was nominally associated with
high-density lipoprotein cholesterol, BMI, and type 2 diabetes;
rs1550532 was nominally associated with fasting insulin,
HOMA-IR, and coronary heart disease.
Causal inference analysis between serum calcium levels
and migraine headache
We utilized a statistical method for estimating causal effects
based on multi-SNP genetic instruments using summary data
alone, using a two-sample Mendelian Randomization (MR) de-
sign based on summary statistics. In the two-stage design, asso-
ciation data from both the intermediate trait (in this case,
serum calcium levels) and the endpoint (migraine headache)
are obtained from two separate genome-wide studies. This
study design is a valid approach to infer causal effects (23).
Briefly, if genetic variants (SNPs) are unlinked, and further if the
effects of each SNP on levels of serum calcium levels are log-
additive, a causal effect (alpha-hat) and the error between a bio-
marker and outcome can be estimated by (24):
ba ¼
X
j
wjbb jr2jX
j
w2j r
2
j
(1)
SEðbaÞ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1X
j
w2j r
2
j
vuut (2)
where for all j SNPs, bj represents the estimated natural log
odds effect of the j-th SNP on the endpoint of interest, rj repre-
sents the standard error on the log odds effect of the j-th SNP on
the endpoint, and wj represents a weight for the SNP on the out-
come. Each SNP was weighted using the reported estimated ef-
fect of the SNP on serum calcium levels (in units of mg/dl). The
significance of the estimate was assessed via the ratio of the
above quantities (i.e. alpha-hat/SE(alpha-hat)), which is chi-
squared distributed with 1 degree of freedom. Effects of each
variant used in our genetic risk score on migraine headache
were obtained from the genome-wide association data set from
the International Migraine Headache Genetics Consortium (5),
the same used in the heritability analysis described above, and
we also included additional stratified analyses with (5,118 cases,
74,239 controls) and without (7,107 cases and 69,427 controls)
aura. Our two-stage design assumed that samples are non-
overlapping between the endpoint (Migraine Headache Genetics
consortium) and the intermediate trait (the Serum Calcium).
Only one study (TwinsUK) was common to both, and only con-
tributed to replication for serum calcium associated variants,
thus, we used estimates from the primary scan which did not
include this study.
We conducted additional sensitivity analysis to examine po-
tential bias in our instruments and robustness of our analyses.
This includes (i) Egger regression using all eight associated se-
rum calcium variants to evaluate systematic bias (25), and (ii)
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the recently reported SIMEX method designed evaluate the ‘no
measurement error’ assumption (41). We also computed a causal
estimate using an unweighted genotype scores (i.e. weights set to
one for all variants). As for the weighted scores, the migraine log-
odds was polarized to the serum calcium-increasing allele. In ad-
dition, we performed a weighted-median method, which can also
assess a causal effect (unbiased asymptotically as sample size in-
creases) and only requires at least 50% of the weight for the score
to derive from valid instruments (40). Weighted median estima-
tion was carried out using the sample code previously made avail-
able (40). Standard error and 95% CI were estimated by
bootstrapping for the median-weighted and Egger regression
approaches. To measure the strength of the genetic instruments,
we calculated F-statistics for each score as previously described
(26), based on the total symmetric sample size of the asymmetric
migraine study design (N¼ 2*(naff * mcontrols)/(naffþmcontrols)).
Supplementary Material
Supplementary Material is available at HMG online.
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